Novo Nordisk (NYSE:NVO) said this week that the CEO of Canadian biotech Novelion Therapeutics, Mary Szela, left Nordisk’s board effective immediately due to a “potential conflict of interest”.
Szela’s departure follows Novelion’s decision to expand into non-alcoholic steatohepatitis, also known as fatty liver, according to a Nordisk spokeswoman. As the Danish drugmaker faces increasing pricing pressure to its core insulin business, Nordisk is looking to diversity beyond diabetes and NASH is reportedly an area of interest.
NASH, a progressive liver disease, is common in nations with rising rates of obesity and diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post Novelion CEO leaves Nordisk board due to potential conflict of interest | Personnel Moves – May 16, 2017 appeared first on MassDevice.